Retatrutide set the current benchmark for obesity peptides — a weekly injectable triple agonist that reported roughly 25% weight loss in Phase 3. Bioglutide, development code NA-931, is coming at the same problem from a different angle: an oral, once-daily pill described as a quadruple agonist, adding an IGF-1 pathway on top of retatrutide's three targets and pitching muscle preservation as its differentiator.
The two are not a clean "which is better." Retatrutide has deeper reported weight loss and far more clinical maturity; bioglutide trades some of that depth for an oral route, a milder tolerability profile in early data, and a muscle-sparing claim. This is a comparison of tradeoffs, not a winner — and only one of the two is something a researcher can actually access today.
Research-context information only. Bioglutide (NA-931) and retatrutide are investigational drugs not approved by the FDA. Protocols, doses, and reactions reported below come from published clinical trials, conference abstracts, and self-reported community sources. This article reports what has been documented, not what should be done. Possession or use of investigational drugs outside an authorized clinical trial may be illegal in your jurisdiction. Consult a licensed physician for personal medical decisions.
Quick Comparison
| Bioglutide (NA-931) | Retatrutide | |
|---|---|---|
| Class | Quadruple agonist (IGF-1 / GLP-1 / GIP / glucagon), as reported in trial data | Triple agonist (GLP-1 / GIP / glucagon) |
| Route | Oral, once daily, food-independent | Subcutaneous injection, weekly |
| Reported weight loss | 13.8% mean at 150 mg/day (Phase 2, ADA 2025 abstract 2189-LB) | 24.2% at 48 wk (Phase 2, NEJM 2023); 25.0% at 80 wk (Phase 3 TRIUMPH-1) |
| Clinical stage | Phase 2 (NCT06564753) | Phase 3 (TRIUMPH program) |
| Muscle data | Abstract titled "Reduces Body Weight without Muscle Loss" (ADA 2025, 143-OR) | Body-composition sub-analyses ongoing across TRIUMPH |
| GI tolerability | Reported mild in Phase 2 abstract | Dose-related GI events; nausea reported in ~42% at top dose (TRIUMPH-1) |
| Available to research now | Not yet in our vetted lineup | Yes — stocked by research vendors |
Mechanism: Triple vs Quadruple Agonism
Retatrutide activates three receptors: GLP-1 (appetite suppression, delayed gastric emptying), GIP (insulin secretion and fat metabolism), and glucagon (energy expenditure and lipolysis). The glucagon arm is what separated it from the dual agonists before it, adding a direct metabolic-rate mechanism on top of appetite suppression.
Bioglutide is described as covering those same three pathways and adding a fourth: IGF-1 signaling. The IGF-1 component is framed as the basis for the compound's muscle-preservation angle — the idea being that an anabolic/growth-axis signal counterbalances the lean-mass loss that tends to accompany rapid weight reduction. That four-target design is why the compound is informally tagged a "quadruple" or "GLP-4" agonist in research-community shorthand. As with "GLP-5" for the quintuple agonists, the label is colloquial — there is no receptor literally named GLP-4, and the IGF-1 mechanism is distinct from the incretin receptors the other three targets sit on.
Mechanistically the two overlap on three of four axes. The open question the trials will answer is whether the added IGF-1 pathway delivers the muscle-sparing effect reported to date, and whether it does so without offsetting the weight loss.
Delivery: Oral Daily vs Injectable Weekly
This is the most concrete difference between the two. Retatrutide is a subcutaneous injection taken once weekly — the same format as the approved incretin drugs. Bioglutide is described as an oral tablet taken once daily and, per the trial data, absorbed independently of food, which would remove the fasting-window requirement that has complicated other oral peptide formulations.
Oral small-molecule delivery is the harder pharmaceutical problem — peptides and peptide-like molecules are notoriously difficult to absorb through the gut — so a food-independent daily oral obesity agent, if the Phase 3 data holds, would be a meaningful format advantage over any injectable. Retatrutide's counterpoint is maturity: the weekly-injection route is well characterized across thousands of TRIUMPH participants, whereas bioglutide's oral route has only Phase 1 and Phase 2 data behind it so far.
Weight Loss: What the Trials Reported
The efficacy gap, as reported to date, favors retatrutide — but the trials are not matched, so the comparison is directional, not head-to-head.
Retatrutide. The Phase 2 trial (Jastreboff et al., NEJM 2023) reported 24.2% mean weight loss at 48 weeks on the 12 mg dose, versus 2.1% on placebo. In Phase 3, the TRIUMPH-1 topline (announced May 2026) reported 25.0% mean weight loss at 80 weeks on 12 mg, with a 104-week extension reporting 30.3%. The earlier TRIUMPH-4 readout (December 2025) reported 28.7% at 68 weeks in participants with obesity and knee osteoarthritis. Every one of those figures comes from a multi-hundred-to-multi-thousand-participant trial.
Bioglutide. The Phase 2 abstract (ADA 2025, poster 2189-LB, published in Diabetes) reported 13.8% mean weight loss at 150 mg/day, with 72% of participants reaching at least 12% weight loss versus 2% on placebo. Earlier Phase 1 data (published in Endocrine Practice) described roughly 10–13% weight loss over 12 weeks. Bioglutide's trials are shorter and earlier-stage than retatrutide's, so the lower headline number partly reflects trial length and dose-titration stage, not only intrinsic potency.
Put plainly: retatrutide has reported deeper weight loss across longer, larger, later-stage trials. Bioglutide's numbers come from a Phase 2 program that is still early. A fair read is that retatrutide currently leads on documented efficacy depth, while bioglutide's ceiling is not yet established.
Muscle Preservation: Bioglutide's IGF-1 Angle
The most distinctive claim in the bioglutide data is muscle preservation. The ADA 2025 oral presentation (abstract 143-OR) was titled "Reduces Body Weight without Muscle Loss," and that effect is attributed to the compound's IGF-1 pathway. Lean-mass retention has become a central question for the whole obesity-drug class, because a substantial fraction of the weight lost on high-efficacy incretin agents is lean tissue rather than fat alone.
Retatrutide's body-composition data is being examined through sub-analyses of the TRIUMPH program rather than headlined as a muscle-sparing feature. Community sources and trialists commonly describe lean-mass loss as a general concern across the incretin-agonist class, which is part of why an explicitly muscle-preserving mechanism is the angle the bioglutide data has emphasized.
The caveat is stage: the muscle-preservation finding sits in a Phase 2 conference abstract, not a peer-reviewed Phase 3 readout. Whether it survives larger, longer trials is unresolved.
Tolerability and GI Side Effects
Gastrointestinal side effects — nausea, vomiting, diarrhea, constipation — are the defining tolerability issue for every incretin-based obesity agent. Retatrutide's TRIUMPH-1 data reported dose-related GI events, with nausea in roughly 42%, diarrhea in ~32%, constipation in ~26%, and vomiting in ~25% of participants on the top dose. These were mostly mild-to-moderate and are consistent with the drug class.
Bioglutide's Phase 2 abstract described GI adverse events as mild. That is an early, abstract-level characterization rather than a full published safety table, so it carries less weight than retatrutide's Phase 3 dataset — but if a milder GI profile holds up in later trials, it would pair naturally with the oral, food-independent format. As with the efficacy and muscle claims, the tolerability comparison is provisional until bioglutide has Phase 3 data.
Availability: One You Can Research Now, One You Can't
Here the two diverge completely. Bioglutide isn't in our vetted vendor lineup yet — it is an investigational Phase 2 compound with no FDA-approved product and no established presence in the research-peptide catalogs we track. Early gray-market listings are beginning to surface; until a source we've vetted for identity and COA carries it, treat any current listing as unverified.
Retatrutide, by contrast, is stocked by research-peptide vendors and shares three of the four pathways bioglutide is described as targeting. Readers tracking the quadruple-agonist concept often follow retatrutide's trial data as the closest available reference point for how those shared pathways behave in humans.
This section includes affiliate links; The Peptide Catalog may earn a commission on purchases.